1. With a run-rate over US$ 450 million in sales and rapid growth in this segment, QIAGEN believes it is a leader in molecular diagnostics, excluding viral load testing and blood screening.
2. The acquisition of DxS brings to QIAGEN a portfolio of molecular diagnostic assays and intellectual property, as well as a deep pipeline of active or planned companion diagnostic partnerships in oncology with many of the leading pharmaceutical companies, including seven of the largest drug makers in this field.
3. QIAGEN Co. Ltd. has a large number of professionals and has developed and produced more than 20 types of PCR detection kits. It has received the most production approval certificates in this field in China.
4. QIAGEN employs more than 3, 400 people in over 30 locations worldwide.
5. In 2005. QIAGEN is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins.
6. Personalized Healthcare: QIAGEN believes that this is the most transformative area of molecular diagnostics.
7. QIAGEN is the leading provider of sample and assay technologies.
8. WuXi AppTec will use QIAGEN`s technologies for a broad range of applications in support of drug discovery and development on behalf of the company`s and QIAGEN`s customers.
9. QIAGEN`s sample and assay technologies are an integral part of research and development laboratories at many of the world's leading pharmaceutical companies.
10. It was used to screen 325 serum samples, which were simultaneously detected by an ELISA kit. Results Our ELISA showed high specificity and sensitivity in the detection of HHV 7-specific IgG and IgM antibodies in clinical samples. Compared with the ELISA kit produced by Qiagen Compy, the sensitivity, specificity and coincident rate of our ELISA using recombinant protein for IgG were 98.1%, 94.1% and 97.8% respectively, and that for IgM were 84.6%, 99.7% and 99.1% respectively. The recombinant protein was more specific but less sensitive than the cells lysates.
结果采用细胞工程抗原和重组抗原制备的HHV7 IgG和IgM ELISA诊断试剂敏感性、特异性、稳定性及重复性［变异系数0%］较好；以Qiagen公司ELISA试剂盒为参比，重组抗原IgG ELISA检测上述标本的敏感性、特异性和符合率分别为98.1%、94.1%和97.8%，IgM ELISA分别为84.6%、99.7%和99.1%；与细胞工程抗原相比，重组抗原诊断试剂的特异性高而敏感性略低。
11. The alkaline lysis method for extraction of plasmid DNA can meet the basic needs of genetic engineering experiments, and plasmid DNA purified with QIAGEN anion exchange resin column was much better.
12. Results the content, purity and yield of plasmid dna from c and d method were higher than a and b method. these plasmid dna were digested with double restriction endonucleases. conclusion the alkaline lysis method for extraction of plasmid dna can meet the basic needs of genetic engineering experiments, and plasmid dna purified with qiagen anion exchange resin column was much better.